Physician profile
Robert James Capps
NPI 1336234376
$8,664.56
in general payments reported to CMS, 2019-2025
32 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,951 · 2020: $1,745 · 2021: $1,408 · 2022: $2,196 · 2023: $1,084 · 2024: $165 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,284 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,284.44 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,654.38 | 2019-2023 | Otezla, Enbrel, Evenity |
| Abbvie INC. | $1,396.48 | 2019-2023 | Rinvoq, Skyrizi, Humira |
| Novartis Pharmaceuticals Corporation | $950.80 | 2019-2025 | |
| Janssen Biotech, INC. | $756.86 | 2019-2023 | Tremfya, Remicade, Stelara |
| Pfizer INC. | $682.52 | 2019-2023 | |
| Ucb, INC. | $496.95 | 2019-2023 | Cimzia |
| Glaxosmithkline, LLC. | $471.75 | 2019-2023 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $386.58 | 2019-2022 | |
| Lilly USA, LLC | $270.43 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $204.52 | 2021-2023 | Saphnelo |
| Radius Health, INC. | $176.93 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $172.00 | 2019-2020 | |
| Genzyme Corporation | $142.23 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $137.04 | 2021-2023 | Lupkynis |
| Sobi, INC | $108.14 | 2019-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $101.62 | 2020 | |
| Genentech USA, INC. | $86.12 | 2019-2023 | Actemra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.02 | 2019-2022 | |
| Lundbeck LLC | $68.56 | 2019-2022 | |
| Horizon Therapeutics Plc | $45.31 | 2022-2023 | Krystexxa |
| Amneal Pharmaceuticals LLC | $43.24 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $35.38 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $34.44 | 2022-2023 | Acthar |
| Pacira Therapeutics, INC. | $32.35 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $31.82 | 2022-2023 | Truxima |
| Celgene Corporation | $21.39 | 2019 | |
| Hospira, INC. | $19.75 | 2022 | |
| Gilead Sciences, INC. | $18.78 | 2020 | |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Biogen, INC. | $15.08 | 2021 | |
| Merck Sharp & Dohme LLC | $11.09 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Capps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.